Distribution of platinum in blood and perilymph in relation to cisplatin induced ototoxicity in the guinea pig

Hearing Research

Volumn 247, Issue 1, 2009, Pages 34-39

  Sepmeijer, Jan Willem ^a   Klis, Sjaak F L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cisplatin; Compound action potential; Ototoxicity; Perilymph; Plasma

Indexed keywords

CISPLATIN; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY STIMULATION; AUDITORY THRESHOLD; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; ELECTROCOCHLEOGRAPHY; ELECTRODE; GUINEA PIG; NONHUMAN; OTOTOXICITY; PERILYMPH; PRIORITY JOURNAL;

ACTION POTENTIALS; ANIMALS; ANTINEOPLASTIC AGENTS; AUDITORY THRESHOLD; CISPLATIN; COCHLEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODES; GUINEA PIGS; HEARING LOSS; MALE; MODELS, ANIMAL; PERILYMPH; PLATINUM;

EID: 57649210508     PISSN: 03785955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.heares.2008.10.001     Document Type: Article

References (25)

1. Andersson A., and Ehrsson H. Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate. J. Chromatogr. 652 2 (1994) 203-210
2. Blakley B.W., Gupta A.K., Myers S.F., and Schwan S. Risk factors for ototoxicity due to cisplatin. Arch. Otolaryngol. Head Neck Surg. 120 5 (1994) 541-546
3. Cappaert N.L., Klis S.F.L., Wijbenga J., and Smoorenburg G.F. Acceleration of cisplatin ototoxicity by perilymphatic application of 4-methylthiobenzoic acid. Hear. Res. 203 1-2 (2005) 80-87
4. Desoize B., Marechal F., Millart H., and Cattan A. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed. Pharmacother. 45 4-5 (1991) 203-207
5. Ekborn A., Lindberg A., Laurell G., Wallin I., Eksborg S., and Ehrsson H. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother. Pharmacol. 51 1 (2003) 36-42
6. Fay R.R. Hearing in Vertebrates: A Psychophysics Databook (1988), Hill-Fay Associates, Winnetka, Illinois
7. Gamelin E., Allain P., Maillart P., Turcant A., Delva R., Lortholary A., and Larra F. Long-term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother. Pharmacol. 37 1-2 (1995) 97-102
8. de Jongh F.E., Verweij J., Loos W.J., de Wit R., de Jonge M.J.A., Plating A.S.T., Nooter K., Stoter G., and Sparreboom A. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J. Clin. Oncol. 19 17 (2001) 3733-3739
9. Klis S.F.L., O'Leary S.J., Hamers F.P.T., de Groot J.C.M.J., and Smoorenburg G.F. Reversible cisplatin ototoxicity in the albino guinea pig. Neuroreport 11 3 (2000) 623-626
10. Klis S.F.L., O'Leary S.J., Wijbenga J., de Groot J.C.M.J., Hamers F.P.T., and Smoorenburg G.F. Partial recovery of cisplatin-induced hearing loss in the albino guinea pig in relation to ciplatin dose. Hear. Res. 164 1-2 (2002) 138-146
11. Lanvers-Kaminsky C., Krefeld B., Dinnesen A.G., Deuster D., Seifert E., Würthwein G., Jaehde U., Pieck A.C., and Boos J. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr. Blood Cancer 47 2 (2006) 183-193
12. Laurell G., and Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100 7 (1990) 724-734
13. Laurell G., Andersson A., Engstrom B., and Ehrsson H. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother. Pharmacol. 36 1 (1995) 83-86
14. Nakai Y., Konishi K., Chang K.C., Ohashi K., Morisaki N., Minowa Y., and Morimoto A. Ototoxicity of the anticancer drug cisplatin. An experimental study. Acta Otolaryngol. 93 3-4 (1982) 227-232
15. O'Leary S.J., Klis S.F.L., de Groot J.C.M.J., Hamers F.P.T., and Smoorenburg G.F. Perilymphatic application of cisplatin over several days in albino guinea pigs: dose-dependency of electrophysiological and morphological effects. Hear. Res. 154 1-2 (2001) 135-145
16. Prestayko A.W., D'Aoust J.C.D., Issell B.F., and Crooke S.T. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat. Rev. 6 1 (1979) 17-39
17. Salas S., Mercier C., Ciccolini J., Pourroy B., Fanciullino R., Tranchand B., Monjanel-Mouterde S., Baciuchka-Palmaro M., Dupuis C., Yang C., Balti M., Lacarelle B., Duffaud F., Durand A., and Favre R. Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther. Drug Monit. 28 4 (2006) 532-539
18. Salt A.N., Kellner C., and Hale S. Contamination of perilymph from the basal cochlear turn with cerebrospinal fluid. Hear. Res. 182 1-2 (2003) 24-33
19. Schweitzer V.G. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 103 4 Pt 2 (1993) 1-52
20. Shinomori Y., Spack D.S., Jones D.D., and Kimura R.S. Volumetric and dimensional analysis of the guinea pig inner ear. Ann. Otol. Rhinol. Laryngol. 110 1 (2001) 91-98
21. Stengs C.H.M., Klis S.F.L., Huizing E.H., and Smoorenburg G.F. Cisplatin-induced ototoxicity; electrophysiological evidence of spontaneous recovery in the albino guinea pig. Hear. Res. 111 1-2 (1997) 103-113
22. Stengs C.H.M., Klis S.F.L., Huizing E.H., and Smoorenburg G.F. Cisplatin ototoxicity. An electrophysiological dose-effect study in albino guinea pigs. Hear. Res. 124 1-2 (1998) 99-107
23. Tothill P., Klys H.S., Matheson L.M., McKay K., and Smyth J.F. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur. J. Cancer 28A 8-9 (1992) 1358-1361
24. Vermorken J.B., van der Vijgh W.J.F., Klein I., Hart A.A.M., Gall H.E., and Pinedo H.M. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat. Rep. 68 3 (1984) 505-513
25. Vermorken J.B., van der Vijgh W.J.F., Klein I., Gall H.E., van Groeningen C.J., Hart G.A.M., and Pinedo H.M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin. Pharmacol. Ther. 39 2 (1986) 136-144